Diffuse Lung Disease & Interstitial Lung Disease Archives - Page 2 of 3 - PulmCCM
Advertisement


Diffuse Lung Disease & Interstitial Lung Disease Articles

Dec 262011
 

Noble et al report results of two Phase III placebo-controlled trials in N. America and Europe, with 779 patients total. In one trial, pirfenidone reduced FVC decline by ~4% at 72 weeks; in the other, it did not; pooling all the data, pirfenidone reduced FVC decline by 2.5% compared to placebo. There were abundant mild [… read more]

Nov 092011
 

Duke’s Momen Wahidi and other luminaries bring you a consensus statement on use of peri-procedure medications during bronchoscopy. I’m assuming you’ve done a few already, so here are some highlights (with slight liberties in paraphrasing): Use topical anesthesia as well as moderate sedation in all patients, unless there are contraindications or you practice at a secret CIA prison. [… read more]

Oct 232011
 

Talc pleurodesis is 90-95% effective at prevention of recurrent primary spontaneous pneumothorax. However, there have been reports of ARDS occurring after talc pleurodesis, mostly in patients with malignant pleural effusions, raising concerns over its use. Bridevaux et al report results of talc pleurodesis on 418 patients with primary spontaneous pneumothorax (PSP) at nine centers in Europe and [… read more]

Oct 222011
 

Is bronchoalveolar lavage useful in the diagnosis and management of interstitial lung disease? Meyer and Raghu believe so (although their manuscript title suggests they’re not 100% sure). They explain why in the October ERJ. They argue that if interpreted in the right clinical context, certain bronchoalveolar lavage findings can help cinch the diagnosis of ILD: Lymphocytes >= 25%: [… read more]

Idiopathic pulmonary fibrosis: Tyrosine kinase inhibitor BIBF 1120 appeared helpful

 Diffuse Lung Disease & Interstitial Lung Disease, Randomized Controlled Trials  Comments Off on Idiopathic pulmonary fibrosis: Tyrosine kinase inhibitor BIBF 1120 appeared helpful
Sep 222011
 

Lung fibrosis is partially mediated by tyrosine kinase pathways. BIBF 1120 is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) — all receptors known to be involved in lung fibrosis. Supported by Boehringer Ingelheim, Richeldi et al randomized 432 patients with [… read more]

Sep 022011
 

September’s Current Opinion in Pulmonary Medicine has 4-5 review articles each on sarcoidosis (how to handle calcium problems; cardiac sarcoid); interstitial lung disease (biologics for connective-tissue disease related ILD; LAM therapies; stem cell therapy for pulmonary fibrosis), and pulmonary vascular disease. Curr Opin Pulm Med 2011;17.

Pirfenidone’s long trudge to FDA approval: InterMune launches new trial (ASCEND-3)

 Diffuse Lung Disease & Interstitial Lung Disease, Randomized Controlled Trials  Comments Off on Pirfenidone’s long trudge to FDA approval: InterMune launches new trial (ASCEND-3)
Aug 132011
 

Unimpressed by the unimpressive results of the CAPACITY trials testing pirfenidone for idiopathic pulmonary fibrosis, the FDA bucked its advisory panel (which had recommended approval) and insisted on another randomized trial in order to reconsider the drug. In July 2011 InterMune started enrollment for ASCEND, which plans to provide results on pirfenidone vs. placebo in [… read more]

Heroes come home from Iraq, Afghanistan with constrictive bronchiolitis

 Clinic and Consults, Diffuse Lung Disease & Interstitial Lung Disease  Comments Off on Heroes come home from Iraq, Afghanistan with constrictive bronchiolitis
Jul 202011
 

King et al report a series of 80 otherwise healthy young vets who failed a 2-mile run fitness test due to dyspnea at Fort Campbell, KY. Many had been exposed to sulfur fires or other inhalational exposures. Among 49 who underwent open lung biopsy, 38 had constrictive bronchiolitis, an extremely rare condition in otherwise healthy [… read more]

Progressive massive fibrosis in coal miners on the rise

 Diffuse Lung Disease & Interstitial Lung Disease  Comments Off on Progressive massive fibrosis in coal miners on the rise
Jun 182011
 

After 25 years of declines in coal workers’ pneumoconiosis (thanks to federal regulation of tolerable concentrations of coal dust and radiographic surveillance of miners), CWP and progressive massive fibrosis have been on the upswing since 2001, killing or disabling dozens of relatively young miners. Wade et al describe the trend in a cohort of 138 [… read more]

Jun 172011
 

Pulmonary rehabilitation, realities in clinical practice. Birnbaum S, CHEST 2011;139:1498-1502. Having trouble finding a pulmonary rehab program to refer your COPD patient into? That may be because in 2011, according to Mr. Birnbaum, Medicare paid outpatient centers $28 per rehabilitation session, per patient.

Tuberous sclerosis with LAM can present in adults

 Diffuse Lung Disease & Interstitial Lung Disease  Comments Off on Tuberous sclerosis with LAM can present in adults
Jun 172011
 

Due to its characteristic brain tumors causing intellectual delay and seizures, TSC-LAM usually presents in childhood. Seibert et al report a series of 79 adult women with TSC-LAM, 45 of whom were diagnosed in adulthood. 15 did not meet diagnostic criteria until after age 18. Ann Intern Med 2011;154:806-813.

Sirolimus improved chylous pleural effusions, lung function in LAM

 Diffuse Lung Disease & Interstitial Lung Disease, Pleural Disease  Comments Off on Sirolimus improved chylous pleural effusions, lung function in LAM
Jun 132011
 

Taveira-DaSilva reports an observational series of 19 women treated with sirolimus for lymphangioleiomyomatosis. Of 12 women with chylous pleural effusions, most had a large improvement or resolution in their effusions. Ann Intern Med 2011;154:797-805. In a randomized trial of 89 LAM patients published in NEJM March 2011, sirolimus reduced decline of lung function.